# Kenvue (KVUE) Financial Model Free Excel 3-statement financial model and company analysis for Kenvue. - Canonical: https://finamodel.com/companies/kenvue - Industry: Consumer Goods - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/KVUE.xlsx ## Model Purpose This model provides a standalone equity valuation and three-statement forecast for Kenvue Inc. to help an analyst determine whether the pending $48.7 billion acquisition offer from Kimberly-Clark ($21.01 per share) represents fair value for shareholders. ## Company Overview Kenvue is the world's largest pure-play consumer health company by revenue, manufacturing and marketing a portfolio of iconic, science-backed brands including Tylenol, Neutrogena, Listerine, and Band-Aid. The company operates at the intersection of healthcare and consumer packaged goods, providing everyday care products across multiple categories. Business segments include: * Self Care (approx. 42% of revenue) * Essential Health (approx. 30% of revenue) * Skin Health and Beauty (approx. 28% of revenue) Key geographies include North America (approx. 50% of revenue), Europe, Middle East and Africa (21%), Asia Pacific (19%), and Latin America (10%). Kenvue operates an asset-light consumer packaged goods business model, though it maintains a significant in-house manufacturing footprint that delivers approximately 60% of its sales volume. The company holds a market-leading competitive position globally, competing with consumer health divisions of Procter & Gamble, Unilever, Haleon, and L'Oréal. Recent major events include its 2023 spin-off from Johnson & Johnson, the 2024 "Our Vue Forward" restructuring programme, and the November 2025 announcement of a pending acquisition by Kimberly-Clark. ## Revenue Deep Dive ### Self Care * **Segment name:** Self Care * **Revenue driver formula:** Base Volume x (1 + Volume Growth) x Base Price x (1 + Value Realisation Growth) * **Historical growth rate:** (1.0%) to +2.0% * **Key growth levers and headwinds:** Driven by seasonal cold, cough, and flu incidences, allergy seasons, and pricing power. Headwinds include subdued seasonal incidences and trade inventory reductions. * **Pricing dynamics:** Highly competitive but supported by strong brand equity (e.g., Tylenol, Motrin), allowing for consistent value realisation (price and mix). * **Revenue recognition notes:** Recognised at a point in time upon transfer of control to the customer (retailers and distributors). * **Seasonality:** Strongest in Q1 and Q4 due to the Northern Hemisphere cold and flu season. ### Skin Health and Beauty * **Segment name:** Skin Health and Beauty * **Revenue driver formula:** Base Volume x (1 + Volume Growth) x Base Price x (1 + Value Realisation Growth) * **Historical growth rate:** (2.0%) to +3.0% * **Key growth levers and headwinds:** Driven by premiumisation, new product innovation, and digital marketing. Headwinds include intense competition in the US market and macroeconomic softness in China. * **Pricing dynamics:** Highly competitive spot pricing with heavy reliance on promotional activity and influencer-led marketing. * **Revenue recognition notes:** Standard point-in-time recognition upon delivery. * **Seasonality:** Relatively balanced, with slight peaks in Q2 and Q3 for sun care products (e.g., Neutrogena sunscreens). ### Essential Health * **Segment name:** Essential Health * **Revenue driver formula:** Base Volume x (1 + Volume Growth) x Base Price x (1 + Value Realisation Growth) * **Historical growth rate:** +3.0% to +6.0% * **Key growth levers and headwinds:** Driven by emerging market penetration and staple demand for oral care and wound care. Headwinds include private label substitution during inflationary periods. * **Pricing dynamics:** Stable pricing environment with moderate contractual and spot price increases. * **Revenue recognition notes:** Standard point-in-time recognition. * **Seasonality:** Minimal seasonality; represents steady, recurring staple purchases. ## Cost Structure ### Variable Costs / COGS * **Line-by-line breakdown:** Raw materials, packaging, direct labour, third-party manufacturing costs, freight, and warehousing. * **Gross margin range:** 56.0% to 58.5% reported (58.0% to 60.5% adjusted). * **Key input costs and commodity exposures:** Petrochemical derivatives, agricultural commodities, paper, and plastics. * **How COGS scales with revenue:** Largely linear with volume, though supply chain optimisation initiatives (e.g., global footprint rationalisation) provide slight operating leverage. ### Operating Expenses * **R&D:** Typically 2.5% to 3.0% of revenue, covering clinical studies, formulation development, and consumer insights research. * **SG&A:** Major components include brand support (advertising and marketing), selling expenses, and general corporate overhead. Brand support is highly variable and actively managed to defend market share. * **Depreciation & Amortisation:** Approximately 3.0% to 4.0% of revenue, heavily weighted towards amortisation of legacy intangible assets. * **Stock-Based Compensation:** Approximately 0.5% to 1.0% of revenue. * **Restructuring / one-time charges:** Frequent in recent years due to the JNJ separation and the "Our Vue Forward" initiative, which includes workforce reductions and asset impairments. ### Margin Profile * **Gross margin:** 57.0% to 58.5% * **EBITDA margin:** 22.0% to 24.0% (Adjusted) * **Operating margin:** 14.0% to 16.0% reported (20.0% to 22.0% adjusted) * **Net margin:** 9.0% to 10.0% * **Margin trend:** Expanding on an adjusted basis due to supply chain efficiencies and restructuring savings, though reported margins are volatile due to impairment charges. ## Balance Sheet Structure * **Total assets:** Approximately $33.0 billion. * **Key asset categories:** High concentration in Goodwill and Intangible Assets (trademarks and brand names) resulting from legacy JNJ acquisitions. * **Goodwill & intangibles as % of total assets:** Approximately 60% to 65%. * **Working capital profile:** * **Days Sales Outstanding (DSO):** 35 to 45 days. * **Days Inventory Outstanding (DIO):** 90 to 110 days. * **Days Payable Outstanding (DPO):** 100 to 120 days. * **Net working capital as % of revenue:** Low single digits (often negative or near zero), allowing the company to fund growth efficiently. * **PP&E:** Approximately $3.0 billion, consisting of global manufacturing facilities and the new Summit, New Jersey headquarters. * **Right-of-use assets / operating leases:** Material but manageable, representing approximately $300 million to $400 million. ## Capital Expenditure & Investment * **Capex as % of revenue:** 3.0% to 4.0%. * **Maintenance capex vs. growth capex:** Approximately 60% maintenance and 40% growth (supply chain modernisation and IT infrastructure post-spin). * **Major capex programmes underway or planned:** Completion of the new corporate headquarters and R&D facility in Summit, New Jersey. * **Capitalised software / development costs:** Moderate, primarily related to enterprise resource planning system implementations post-separation. * **M&A pattern:** Historically organic post-spin, though the company is currently the target of a $48.7 billion acquisition by Kimberly-Clark. ## Debt & Capital Structure * **Total debt:** Approximately $8.5 billion. * **Debt/EBITDA ratio:** Approximately 2.5x gross leverage. * **Credit rating:** Investment grade (A- range). * **Key debt instruments:** $7.75 billion in senior unsecured notes issued at spin-off, plus additional 2025 note issuances and a $4.0 billion commercial paper programme. * **Maturity profile:** Staggered maturities ranging from 2025 to 2063. * **Interest rate profile:** Predominantly fixed-rate senior notes with a weighted average cost of debt around 4.5% to 5.0%. * **Covenants:** Standard investment-grade financial covenants on the $4.0 billion revolving credit facility. * **Share repurchase programme:** Active prior to the Kimberly-Clark merger agreement (repurchased ~$197 million in early 2025). * **Dividend policy:** Annualised dividend of $0.83 per share, representing a payout ratio of approximately 75% of adjusted earnings and a yield of roughly 4.5%. ## Cash Flow Characteristics * **Operating cash flow conversion:** 1.2x to 1.5x (OCF / Net Income), driven by high depreciation and amortisation add-backs. * **Free cash flow margin:** 10.0% to 12.0% (FCF / Revenue). * **Major non-cash items:** Depreciation, amortisation of intangibles, asset impairments, and stock-based compensation. * **Working capital cash flow impact:** Generally a slight source of cash due to strong payable management. * **Capex intensity:** Low to moderate (3.0% to 4.0% of revenue). * **Cash tax rate vs. GAAP effective tax rate:** Cash taxes are typically lower than the GAAP effective rate due to timing differences in intangible amortisation and restructuring provisions. ## Sheet Structure 1. **Assumptions**: Hardcoded drivers for macroeconomic inputs, segment volume growth, value realisation, margin targets, and tax rates. 2. **Revenue Build**: Detailed forecast of Self Care, Skin Health and Beauty, and Essential Health revenues, split by volume and value realisation (price/mix). 3. **Income Statement**: Consolidated P&L from Net Sales down to Net Income, matching the 10-K format (Net Sales, Cost of Sales, Gross Profit, Selling General and Administrative, R&D, Restructuring, Operating Income). 4. **Balance Sheet**: Standard asset, liability, and equity lines, with specific breakouts for Goodwill, Intangible Assets, and Short-Term Debt. 5. **Cash Flow Statement**: Indirect method starting from Net Income, adjusting for D&A and impairments, changes in working capital, capex, debt issuance/repayment, and dividends. 6. **Working Capital Schedule**: Calculation of Accounts Receivable, Inventory, and Accounts Payable based on DSO, DIO, and DPO assumptions. 7. **Debt & Interest Schedule**: Tranche-by-tranche breakdown of senior notes, commercial paper, and revolving credit facility, calculating interest expense and tracking maturities. 8. **Depreciation & Amortisation Schedule**: Waterfall of existing PP&E and intangibles, plus capex additions and associated D&A. 9. **DCF Valuation**: Unlevered free cash flow calculation, WACC build, terminal value, and implied share price to compare against the Kimberly-Clark offer. ## Key Financial Relationships 1. `Self Care Revenue = Prior Year Self Care Revenue * (1 + Self Care Volume Growth + Self Care Value Realisation)` 2. `Skin Health and Beauty Revenue = Prior Year Skin Health and Beauty Revenue * (1 + Skin Health Volume Growth + Skin Health Value Realisation)` 3. `Essential Health Revenue = Prior Year Essential Health Revenue * (1 + Essential Health Volume Growth + Essential Health Value Realisation)` 4. `Total Net Sales = Self Care Revenue + Skin Health and Beauty Revenue + Essential Health Revenue` 5. `Cost of Sales = Total Net Sales * (1 - Gross Margin %)` 6. `Gross Profit = Total Net Sales - Cost of Sales` 7. `SG&A Expense = Total Net Sales * SG&A Margin %` 8. `Adjusted Operating Income = Gross Profit - SG&A Expense - R&D Expense` 9. `Accounts Receivable = (Total Net Sales / 365) * DSO` 10. `Inventory = (Cost of Sales / 365) * DIO` 11. `Accounts Payable = (Cost of Sales / 365) * DPO` 12. `Interest Expense = Average Total Debt * Weighted Average Interest Rate` 13. `Net Income = Operating Income - Interest Expense - Taxes` 14. `Free Cash Flow = Cash from Operations - Capital Expenditures` ## Cross-Sheet Dependencies * The **Assumptions** sheet feeds all growth rates, margin profiles, and working capital days into the **Revenue Build**, **Income Statement**, and **Working Capital Schedule**. * The **Revenue Build** feeds Total Net Sales into the **Income Statement**. * The **Income Statement** generates Net Income, which flows to the top of the **Cash Flow Statement** and feeds Retained Earnings on the **Balance Sheet**. * The **Working Capital Schedule** calculates period-over-period changes that flow into the Operating Cash Flow section of the **Cash Flow Statement**. * The **Debt & Interest Schedule** calculates Interest Expense for the **Income Statement** and ending debt balances for the **Balance Sheet**. * The **Cash Flow Statement** calculates the net change in cash, which links to the Cash and Cash Equivalents line on the **Balance Sheet** to ensure it balances. * The **DCF Valuation** pulls NOPAT, D&A, Capex, and Working Capital changes from the **Income Statement** and **Cash Flow Statement**. ## Sign Convention * **Income Statement:** Revenues are positive. All expenses (COGS, SG&A, R&D, Interest, Taxes) are negative. Net Income is the sum of revenues and negative expenses. * **Balance Sheet:** Assets are positive. Liabilities and Equity are positive. * **Cash Flow Statement:** Cash inflows are positive. Cash outflows (e.g., Capex, dividends paid, debt repayment) are negative. * **Working Capital:** An increase in an asset (e.g., Accounts Receivable) is a negative cash flow. An increase in a liability (e.g., Accounts Payable) is a positive cash flow. ## Things Most Likely to Go Wrong * **Adjusted vs Reported Metrics:** Kenvue reports significant variances between GAAP and Adjusted metrics due to JNJ separation costs and restructuring. The model must clearly distinguish between reported operating income and adjusted operating income to avoid undervaluing the core business. * **Foreign Currency Translation:** FX swings can impact reported revenue by 2% to 3% annually. The model should forecast on a constant-currency basis or explicitly model an FX headwind/tailwind line. * **Intangible Amortisation:** The company carries massive legacy intangible assets. Amortisation heavily depresses GAAP net income but is a non-cash charge. FCF conversion will look artificially high if measured against GAAP net income. * **Pending Acquisition Dynamics:** The model must account for the pending Kimberly-Clark transaction. If modelling as a standalone entity, share repurchases should be paused in the forecast period as per standard merger agreement covenants. * **Volume vs Value Realisation:** Revenue growth has recently been driven entirely by price increases (value realisation) while volumes have declined. Extrapolating historical price increases indefinitely will break the model; volume growth must eventually stabilise. * **Tax Rate Volatility:** The GAAP effective tax rate fluctuates due to jurisdictional mix and discrete tax benefits. Use the adjusted effective tax rate for steady-state forecasting. * **Restructuring Cash Outflows:** While restructuring charges are added back to adjusted earnings, they represent real cash outflows that must be captured in the Cash Flow Statement. * **Seasonality in Working Capital:** Q4 inventory builds for the cold and flu season can distort year-end working capital metrics. Ensure DIO calculations use full-year COGS rather than annualised Q4 COGS. ## Validation Checks * "Gross margin should be in the 57.0% to 60.5% range; flag if outside this band." * "Adjusted Operating Margin should remain between 20.0% and 22.0%." * "Capex as a % of revenue should run between 3.0% and 4.0%." * "Debt/EBITDA should remain below 3.0x to maintain the investment-grade rating." * "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period." * "Effective tax rate should be between 24.0% and 27.0%." * "Dividend payout ratio should remain between 70% and 80% of adjusted net income." * "Implied share price from the DCF should be compared against the $21.01 Kimberly-Clark offer price to assess deal premium." ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | Self Care Volume Growth | (1.0) | % | Reflects recent subdued seasonal incidences and trade inventory reductions | | Self Care Value Realisation | 2.0 | % | Continued pricing power in core OTC brands | | Skin Health Volume Growth | 0.5 | % | Gradual recovery in APAC and stabilisation in North America | | Skin Health Value Realisation | 1.5 | % | Moderate premiumisation and targeted price increases | | Essential Health Volume Growth | 1.5 | % | Steady staple demand and emerging market growth | | Essential Health Value Realisation | 2.5 | % | Strong pricing power in oral and wound care | | Gross Margin (Adjusted) | 60.2 | % | Based on FY25 reported adjusted gross margin | | SG&A as % of Revenue | 36.5 | % | Supports increased brand investment and marketing | | R&D as % of Revenue | 2.7 | % | Historical average required to support innovation pipeline | | Days Sales Outstanding (DSO) | 40 | Days | Based on historical receivables turnover | | Days Inventory Outstanding (DIO) | 100 | Days | Reflects global supply chain requirements | | Days Payable Outstanding (DPO) | 110 | Days | Strong supplier negotiation power | | Capex as % of Revenue | 3.5 | % | Historical average including supply chain optimisation | | Effective Tax Rate | 26.5 | % | Based on FY25 reported effective tax rate | | Weighted Average Interest Rate | 4.8 | % | Blended rate of senior unsecured notes | | Annual Dividend per Share | 0.83 | $ | Current stated dividend policy | | Share Count | 1,920 | Millions | Outstanding shares as of early 2026 | | WACC | 7.5 | % | Standard discount rate for large-cap consumer staples | | Terminal Growth Rate | 2.0 | % | Aligns with long-term global GDP and inflation expectations | ## Data Sources & Benchmarks * **Filings:** Kenvue Investor Relations website (investors.kenvue.com) and SEC EDGAR database for 10-K and 10-Q filings. * **Key Peers:** Procter & Gamble (PG), Unilever (UL), Haleon (HLN), L'Oréal (OR.PA). * **Industry Data:** NielsenIQ or Circana (formerly IRI) for US consumer scanner data and market share tracking. * **Consensus Estimates:** FactSet or Bloomberg for analyst consensus on revenue and adjusted EPS. * **Proprietary Data:** IQVIA for over-the-counter (OTC) pharmacy sales trends globally. ## Sources * Kenvue Q4 and Full Year 2025 Earnings Release (https://www.kenvue.com) * Kenvue 2024 and 2025 Annual Reports on Form 10-K (https://www.sec.gov) * Bayelsa Watch: Kenvue Q4 2025 Earnings Analysis (https://bayelsawatch.com) * Kavout: Kenvue Q4 2025 Earnings Signal (https://kavout.com) * TradingView: Kenvue Inc. SEC 10-K Report Summary (https://www.tradingview.com) --- ## Frequently asked questions ### What is Kenvue and what products does it sell? Kenvue is the world's largest pure-play consumer health company by revenue, manufacturing and marketing iconic, science-backed brands like Tylenol, Neutrogena, Listerine, and Band-Aid. It operates at the intersection of healthcare and consumer packaged goods, providing everyday care products across its Self Care, Essential Health, and Skin Health and Beauty segments. ### What are Kenvue's primary revenue segments and geographic markets? Kenvue's revenue is primarily driven by its Self Care segment (approx. 42%), Essential Health (approx. 30%), and Skin Health and Beauty (approx. 28%). Geographically, North America accounts for about 50% of its revenue, followed by Europe, Middle East and Africa (21%), Asia Pacific (19%), and Latin America (10%). ### What is Kenvue's capital expenditure strategy? Kenvue's capital expenditure typically ranges from 3.0% to 4.0% of revenue, with approximately 60% allocated to maintenance and 40% to growth initiatives. Major capex programs include completing its new corporate headquarters and R&D facility in Summit, New Jersey, alongside investments in supply chain modernization and IT infrastructure post-spin-off. ### What is the purpose of a financial model for Kenvue given the pending acquisition? A financial model for Kenvue is used to provide a standalone equity valuation and three-statement forecast. This helps analysts determine if the pending $48.7 billion acquisition offer from Kimberly-Clark, at $21.01 per share, represents fair value for Kenvue shareholders. ### Can I download an Excel financial model for Kenvue from this site? No, an Excel financial model for Kenvue is not available for download from this site. The provided context describes the purpose and structure of a financial model for Kenvue, rather than offering a downloadable version. ### How does Kenvue manage its working capital? Kenvue maintains a low single-digit or often negative net working capital as a percentage of revenue, allowing it to fund growth efficiently. This is supported by Days Sales Outstanding (DSO) of 35-45 days, Days Inventory Outstanding (DIO) of 90-110 days, and Days Payable Outstanding (DPO) of 100-120 days. [Interactive forecast calculator](https://finamodel.com/companies/kenvue/forecast)